SUNNYVALE, Calif.--(BUSINESS WIRE)--Elixir Medical Corporation, a developer of products that combine state-of-the-art medical devices with advanced pharmaceuticals, announced today that it will release at EuroPCR in Paris the long-term 5-year clinical follow-up data for the DESolve® Novolimus eluting coronary scaffold system, 6-month clinical and imaging data for the 120 µm thin-strut DESolve™ Cx Novolimus eluting coronary bioresorbable scaffold system, and initial clinical results of the PRAVA™ Bioresorbable scaffold system for SFA in the peripheral vasculature. EuroPCR is the annual meeting of the European Association for Percutaneous Cardiovascular Interventions.
Following are some of the highlights of Elixir Medical’s scientific sessions at EuroPCR (in chronological order) at the Palais Des Congres de Paris in Central European Summer Time (CEST):
Tuesday, May 16
12:30, Room 351
Multicentre evaluation of a novel 120µm DESolve Cx BRS: first report
of six-month clinical and imaging endpoints
• Alexandre
Abizaid, MD, PhD, Instituto Dante Pazzanese de Cardiologia, Sao Paulo,
Brazil
12:45, Room 351
Prospective, multicentre evaluation of the DESolve Novolimus-Eluting
coronary BRS: imaging outcomes and four-year clinical and imaging results
•
Stefan Verheye, MD, PhD, ZNA Middleheim Hospital, Antwerp, Belgium
Thursday, May 18
10:41, Room Maillot, Level 2
Elixir Medical DESAPPEAR SFA Study – Initial clinical experience with
the PRAVA bioresorbable scaffold system
• Koen Deloose, MD, AZ
St Blasius Hospital, Dendermonde, Belgium
Friday, May 19
10:30, Room 253
Multicentre, post-marketing evaluation of the Elixir DESolve
Novolimus-Eluting coronary BRS system: 12M results for the DESolve PMCF
study
• Ricardo Costa, MD, Instituto Dante Pazzanese de
Cardiologia, Sao Paulo, Brazil
About Elixir Medical
Elixir Medical Corporation, a privately held company headquartered in Sunnyvale, California, develops products that combine state-of-the-art medical devices with advanced pharmaceuticals to provide innovative treatment solutions to patients worldwide. The company's next-generation drug-eluting stent systems and bioresorbable coronary scaffolds are designed to optimize localized drug delivery to provide safe and effective treatments for cardiovascular patients. For more information, visit www.elixirmedical.com
